Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 541 - 560 results of 49,080 for search '(( 5 ((we decrease) OR (mean decrease)) ) OR ( 50 ((ng decrease) OR (a decrease)) ))', query time: 0.93s Refine Results
  1. 541
    Table_1_Aligned Fingolimod-Releasing Electrospun Fibers Increase Dorsal Root Ganglia Neurite Extension and Decrease Schwann Cell Expression of Promyelinating Factors.DOCX

    Table_1_Aligned Fingolimod-Releasing Electrospun Fibers Increase Dorsal Root Ganglia Neurite Extension and Decrease Schwann Cell Expression of Promyelinating Factors.DOCX by Devan L. Puhl (6294197)

    Published 2020
    Save to List
    Saved in:
  2. 542
    Decreased biofilm formation in the Δ<i>tad123</i> mutant cells.

    Decreased biofilm formation in the Δ<i>tad123</i> mutant cells. by Tra-My Duong-Nu (7300970)

    Published 2019
    Save to List
    Saved in:
  3. 543
    Mean ± SD of the different parameters relative to bipedal stance on soft support with the eyes open recorded in the Chewing and Hand Grip groups.

    Mean ± SD of the different parameters relative to bipedal stance on soft support with the eyes open recorded in the Chewing and Hand Grip groups. by Cristina Dolciotti (16317330)

    Published 2025
    Save to List
    Saved in:
  4. 544
    Sample selection flowchart.

    Sample selection flowchart. by Ronald López (18098572)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 545
    Effect of the Hill coefficient on estimates of <i>ε</i><sub>max</sub> (left column) and IC<sub>50</sub> (right column) for the logistic model with drug applied to the growth rate <i>a</i> (top row) or the carrying capacity <i>b</i> (bottom row).

    Effect of the Hill coefficient on estimates of <i>ε</i><sub>max</sub> (left column) and IC<sub>50</sub> (right column) for the logistic model with drug applied to the growth rate <... by Hope Murphy (8843516)

    Published 2020
    Save to List
    Saved in:
  6. 546
    Partial correlation of <i>ε</i><sub>max</sub> (left column) and IC<sub>50</sub> (right column) estimates at 10 days and 20 days (first and second bar of each color, respectively) on parameters <i>a</i> and <i>b</i> of each model.

    Partial correlation of <i>ε</i><sub>max</sub> (left column) and IC<sub>50</sub> (right column) estimates at 10 days and 20 days (first and second bar of each color, respectively) o... by Hope Murphy (8843516)

    Published 2020
    Save to List
    Saved in:
  7. 547
    Image_5_Where Are We on the Animal Welfare Map? Using GIS to Assess Stakeholder Diversity and Inclusion.TIFF

    Image_5_Where Are We on the Animal Welfare Map? Using GIS to Assess Stakeholder Diversity and Inclusion.TIFF by Kevin C. Roberts (11828714)

    Published 2021
    Save to List
    Saved in:
  8. 548
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 549
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 550
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 551
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 552
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 553
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 554
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 555
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 556
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 557
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 558
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 559
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 560
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: